Dachaigh › Leukemia myeloid geur › North Carolina › Durham
Sgrùdaidhean clionaigeach Leukemia myeloid geur ann an Durham, NC
Tha 33 sgrùdaidhean airson Leukemia myeloid geur a’ lorg phàirtichean aig làraichean ann agus timcheall air Durham (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
A’ fastadhÌre 2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mìle air falbh
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- Durham VA Medical Center, Durham
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
A’ fastadhÌre 2
- Duke University Medical Center, Durham
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
A’ fastadhÌre 2
- Duke University Medical Center, Durham
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
A’ fastadhÌre 2
- Duke University Medical Center, Durham
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
A’ fastadhÌre 2
- Duke University Medical Center, Durham
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
A’ fastadhÌre 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mìle air falbh
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
A’ fastadhÌre 1/2
- Duke University Medical Center, Durham
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
A’ fastadhÌre 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mìle air falbh
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
A’ fastadhÌre 1/2
- UNC School of Medicine, Division of Hematology, Chapel Hill · 10 mìle air falbh
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
A’ fastadhÌre 3
- US-Chapel Hill-UNCNORTHCAROLINA, Chapel Hill · 10 mìle air falbh
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
A’ fastadhÌre 1/2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mìle air falbh
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
A’ fastadhÌre 1
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mìle air falbh
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
A’ fastadhÌre 3
- Duke University Medical Center, Durham
- University of North Carolina, Chapel Hill, Chapel Hill · 10 mìle air falbh
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
A’ fastadhÌre 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mìle air falbh
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
A’ fastadhÌre 1/2
- Research Site, Durham
- Research Site, Chapel Hill · 10 mìle air falbh
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
A’ fastadhÌre 2
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mìle air falbh
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
A’ fastadhSgrùdadh amharc
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mìle air falbh
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
A’ fastadh
- University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mìle air falbh
Registry of Older Patients With Cancer
A’ fastadhSgrùdadh amharc
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mìle air falbh
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
A’ fastadhÌre 2
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · 10 mìle air falbh
A Study of Revumenib and Mezigdomide in People With Leukemia
A’ fastadhÌre 1/2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 mìle air falbh
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
A’ fastadhÌre 1
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · 10 mìle air falbh
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
A’ fastadhÌre 1
- University of North Carolina, Chapel Hill · 10 mìle air falbh
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
A’ fastadhÌre 2/3
- Duke University, Durham
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
A’ fastadhÌre 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 mìle air falbh
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
A’ fastadhÌre 2
- University of North Carolina, Chapel Hill · 10 mìle air falbh
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
A’ fastadhÌre 1
- Duke Blood Cancer Center, Durham
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A’ fastadhÌre 1
- Duke Cancer Center, Durham
Novel Digital Application for Patients With Acute Leukemia
A’ fastadh
- Duke University, Durham
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
A’ fastadhSgrùdadh amharc
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mìle air falbh
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
A’ fastadhÌre 1/2
- Duke University Medical Center, Durham
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
A’ fastadhFàilte do shaor-thoilich fhallain
- Duke University, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mìle air falbh
Sgrùdaidhean Leukemia myeloid geur ann am bailtean eile
- Houston, TX85 sgrùdaidhean
- New York City, NY51 sgrùdaidhean
- Boston, MA44 sgrùdaidhean
- Seattle, WA41 sgrùdaidhean
- Baldwin Park, CA40 sgrùdaidhean
- Columbus, OH35 sgrùdaidhean
- Philadelphia, PA34 sgrùdaidhean
- Atlanta, GA31 sgrùdaidhean
- Tampa, FL29 sgrùdaidhean
- Chicago, IL26 sgrùdaidhean
- Portland, OR25 sgrùdaidhean
- Washington, DC24 sgrùdaidhean
Sgrùdaidhean eile ann an Durham
- Aillse a' bhroilleach64 sgrùdaidhean
- Aillse (gach seòrsa)58 sgrùdaidhean
- Aillse Sgamhain Neo-chealla-beag39 sgrùdaidhean
- Myeloma iomaill37 sgrùdaidhean
- Ailse metastatach33 sgrùdaidhean
- Aillse Prostata32 sgrùdaidhean
- Ailseachadh nan Sgamhan32 sgrùdaidhean
- Aillse colorectal28 sgrùdaidhean
- Cancer Ovarian27 sgrùdaidhean
- Leukemia Lymphocytic Cronach27 sgrùdaidhean
- Fàilligeadh a' Chridhe26 sgrùdaidhean
- Cancer Pancreatic24 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.